AGIOS PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
AGIOS PHARMACEUTICALS, INC. (AGIO) had Debt Securities, Available-for-sale, Unrealized Loss Position of $572.70 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $572.70M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $461.40M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $136.20M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $288.90M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $572.70M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $461.40M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $136.20M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $288.90M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $626.80M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $586.90M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $768.10M 10-K · filed 2026-02-12 |
| 2024-09-30 | $336.60M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $538.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $490.10M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $513.50M 10-K · filed 2025-02-13 |
| 2023-09-30 | $808.10M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $842.20M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $779.30M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $868.20M 10-K · filed 2024-02-15 |
| 2022-09-30 | $881.60M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $968.10M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.07B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $950.50M 10-K · filed 2023-02-23 |
| 2021-09-30 | $692.50M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $559.30M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $248.30M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $299.00M 10-K · filed 2022-02-24 |
| 2020-09-30 | $247.70M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $129.70M 10-Q · filed 2020-07-30 |
| 2019-12-31 | $345.70M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |